493 related articles for article (PubMed ID: 26514402)
21. COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord.
Yiangou Y; Facer P; Durrenberger P; Chessell IP; Naylor A; Bountra C; Banati RR; Anand P
BMC Neurol; 2006 Mar; 6():12. PubMed ID: 16512913
[TBL] [Abstract][Full Text] [Related]
22. Purinergic signaling in retinal degeneration and regeneration.
Reichenbach A; Bringmann A
Neuropharmacology; 2016 May; 104():194-211. PubMed ID: 25998275
[TBL] [Abstract][Full Text] [Related]
23. Purinergic signaling negatively regulates activity of an olfactory receptor in an odorant-dependent manner.
Yu Y; Zhang C
Neuroscience; 2014 Sep; 275():89-101. PubMed ID: 24928349
[TBL] [Abstract][Full Text] [Related]
24. Purinergic neurone-glia signalling in cognitive-related pathologies.
Illes P; Verkhratsky A
Neuropharmacology; 2016 May; 104():62-75. PubMed ID: 26256423
[TBL] [Abstract][Full Text] [Related]
25. Regulation of Microglial Functions by Purinergic Mechanisms in the Healthy and Diseased CNS.
Illes P; Rubini P; Ulrich H; Zhao Y; Tang Y
Cells; 2020 Apr; 9(5):. PubMed ID: 32365642
[TBL] [Abstract][Full Text] [Related]
26. Conversion of extracellular ATP into adenosine: a master switch in renal health and disease.
Dwyer KM; Kishore BK; Robson SC
Nat Rev Nephrol; 2020 Sep; 16(9):509-524. PubMed ID: 32641760
[TBL] [Abstract][Full Text] [Related]
27. [The role of ecto-purines in inflammation leading to demyelination - new means for therapies against multiple sclerosis].
Cieślak M; Komoszyński M
Neurol Neurochir Pol; 2011; 45(5):489-99. PubMed ID: 22127945
[TBL] [Abstract][Full Text] [Related]
28. Strong P2X4 purinergic receptor-like immunoreactivity is selectively associated with degenerating neurons in transgenic rodent models of amyotrophic lateral sclerosis.
Casanovas A; Hernández S; Tarabal O; Rosselló J; Esquerda JE
J Comp Neurol; 2008 Jan; 506(1):75-92. PubMed ID: 17990272
[TBL] [Abstract][Full Text] [Related]
29. Purinergic receptors in multiple sclerosis pathogenesis.
Domercq M; Zabala A; Matute C
Brain Res Bull; 2019 Sep; 151():38-45. PubMed ID: 30500565
[TBL] [Abstract][Full Text] [Related]
30. Pharmacology and structure of P2Y receptors.
von Kügelgen I; Hoffmann K
Neuropharmacology; 2016 May; 104():50-61. PubMed ID: 26519900
[TBL] [Abstract][Full Text] [Related]
31. Knocking down metabotropic glutamate receptor 1 improves survival and disease progression in the SOD1(G93A) mouse model of amyotrophic lateral sclerosis.
Milanese M; Giribaldi F; Melone M; Bonifacino T; Musante I; Carminati E; Rossi PI; Vergani L; Voci A; Conti F; Puliti A; Bonanno G
Neurobiol Dis; 2014 Apr; 64():48-59. PubMed ID: 24361555
[TBL] [Abstract][Full Text] [Related]
32. P2 purinergic receptors signal to STAT3 in astrocytes: Difference in STAT3 responses to P2Y and P2X receptor activation.
Washburn KB; Neary JT
Neuroscience; 2006 Oct; 142(2):411-23. PubMed ID: 16905269
[TBL] [Abstract][Full Text] [Related]
33. [Nucleotide receptors--structure and function, history and perspectives].
Barańska J
Postepy Biochem; 2014; 60(4):424-37. PubMed ID: 25807822
[TBL] [Abstract][Full Text] [Related]
34. [Neuropharmacological study of ATP receptors and their role in neuropathic pain].
Inoue K
Yakugaku Zasshi; 2013; 133(10):1035-9. PubMed ID: 24088347
[TBL] [Abstract][Full Text] [Related]
35. System xC- is a mediator of microglial function and its deletion slows symptoms in amyotrophic lateral sclerosis mice.
Mesci P; Zaïdi S; Lobsiger CS; Millecamps S; Escartin C; Seilhean D; Sato H; Mallat M; Boillée S
Brain; 2015 Jan; 138(Pt 1):53-68. PubMed ID: 25384799
[TBL] [Abstract][Full Text] [Related]
36. Motor neuron dysfunction in a mouse model of ALS: gender-dependent effect of P2X7 antagonism.
Cervetto C; Frattaroli D; Maura G; Marcoli M
Toxicology; 2013 Sep; 311(1-2):69-77. PubMed ID: 23583883
[TBL] [Abstract][Full Text] [Related]
37. Medicinal chemistry of P2 and adenosine receptors: Common scaffolds adapted for multiple targets.
Jacobson KA; IJzerman AP; Müller CE
Biochem Pharmacol; 2021 May; 187():114311. PubMed ID: 33130128
[TBL] [Abstract][Full Text] [Related]
38. Suppression of adenosine 2a receptor (A2aR)-mediated adenosine signaling improves disease phenotypes in a mouse model of amyotrophic lateral sclerosis.
Ng SK; Higashimori H; Tolman M; Yang Y
Exp Neurol; 2015 May; 267():115-22. PubMed ID: 25779930
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of P2X4 function by P2Y6 UDP receptors in microglia.
Bernier LP; Ase AR; Boué-Grabot É; Séguéla P
Glia; 2013 Dec; 61(12):2038-49. PubMed ID: 24123515
[TBL] [Abstract][Full Text] [Related]
40. P2 receptor interaction and signalling cascades in neuroprotection.
Miras-Portugal MT; Queipo MJ; Gil-Redondo JC; Ortega F; Gómez-Villafuertes R; Gualix J; Delicado EG; Pérez-Sen R
Brain Res Bull; 2019 Sep; 151():74-83. PubMed ID: 30593879
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
